MAP2K7 and non-small cell lung carcinoma: Overall, we speculated that NSC609077 shows the potential to be an EGFR-targeted drug that may be used to overcome EGFR-TKI resistance in NSCLC by simultaneously blocking PI3K/AKT and MEK/ERK pathways, a concept that has also been previously proposed [52].